Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study

• Published in: Blood 2017-10, Vol.130 (15), p.1706-1712
• Main Authors: Majeed, Ammar, Ågren, Anna, Holmström, Margareta, Bruzelius, Maria, Chaireti, Roza, Odeberg, Jacob, Hempel, Eva-Lotta, Magnusson, Maria, Frisk, Tony, Schulman, Sam
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Blood Coagulation Factors - adverse effects; Blood Coagulation Factors - therapeutic use; Cohort Studies; Demography; Female; Hemorrhage - drug therapy; Hemorrhage - mortality; Humans; Male; Medicin och hälsovetenskap; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Pyridones - adverse effects; Pyridones - therapeutic use; Rivaroxaban - adverse effects; Rivaroxaban - therapeutic use; Thromboembolism - chemically induced; Treatment Outcome
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood-2017-05-782060

There is uncertainty regarding the effectiveness and occurrence of thromboembolic events in patients treated with prothrombin complex concentrates (PCCs) for the management of major bleeding events (MBEs) on rivaroxaban or apixaban. We investigated the effectiveness of PCCs given for the management of MBEs in patients on rivaroxaban or apixaban. Between 1 January 2014 and 1 October 2016, we prospectively included patients on rivaroxaban or apixaban treated with PCCs for the management of MBEs. The effectiveness of PCCs was assessed by using the International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee criteria for the assessment of the effectiveness of major bleeding management. The safety outcomes were thromboembolic events and all-cause mortality within 30 days after treatment with PCCs. A total of 84 patients received PCCs for the reversal of rivaroxaban or apixaban due to a MBE. PCCs were given at a median (interquartile range) dose of 2000 IU (1500-2000 IU). Intracranial hemorrhage (ICH) was the most common site of bleeding requiring reversal (n = 59; 70.2%), followed by gastrointestinal bleeding in 13 (15.5%) patients. Management with PCCs was assessed as effective in 58 (69.1%) patients and ineffective in 26 (30.9%) patients. Most patients with ineffective hemostasis with PCCs had ICH (n = 16; 61.5%). Two patients developed an ischemic stroke, occurring 5 and 10 days after treatment with PCC. Twenty-seven (32%) patients died within 30 days after a MBE. The administration of PCCs for the management of MBEs associated with rivaroxaban or apixaban is effective in most cases and is associated with a low risk of thromboembolism. Our findings are limited by the absence of a control group in the study. •PCCs for the management of major bleeding in patients on rivaroxaban or apixaban is an effective strategy in most cases.•The thromboembolic complication rate in this setting is low and comparable with that of anticoagulation discontinuation without reversal.